through 2002 for a group of Medicare benefi ciaries who were diagnosed with breast, prostate, lung, or colorectal cancer. We chose these sites because they account for approximately 60% of all cancers in the elderly ( 2 ) . To provide greater understanding of which treatments have contributed to changes in initial cancer care costs, we present trends in the costs of care for specifi c types of health services, such as hospitalizations, chemotherapy, and radiation therapy, in addition to trends in total costs. We hypothesized that the increases in total costs of initial care would refl ect both increased rates of treatment of elderly cancer patients and increased costs of specifi c types of therapy.
Methods

Data Sources
The data for this analysis were from an existing linkage of cancer registry data from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute to Medicare claims records ( 6 ) . Among patients reported to SEER who were aged 65 or older, 94% have been linked to Medicare ' s master enrollment file ( 6 ) . Using the linked SEER -Medicare data allowed us to track patients across different health-care settings for purposes of estimating the costs of cancer treatment during the peri-diagnostic period and throughout the year following diagnosis.
The SEER data are obtained from population-based registries that collect clinical information about incident cancer patients and follow-up vital status. To track cost trends over time, we included only those registries that have been part of the SEER program since 1991. These registries covered fi ve states (Connecticut, Hawaii, Iowa, New Mexico, and Utah) and six metropolitan areas (Atlanta, Detroit, Los Angeles, San Francisco-Oakland, San JoseMonterey, and Seattle), which together represent approximately 14% of the US population ( 2 ) . For each patient, the SEER data contain a unique case number, each occurrence of a primary incident cancer, month and year of diagnosis, type of surgery performed, and stage of disease at diagnosis. The Medicare data, collected by the Center for Medicare and Medicaid Services (CMS), include claims for benefi ciaries with fee-for-service coverage for all inpatient hospitalizations, skilled nursing facility care, outpatient hospital services, physician/supplier services, durable medical equipment, and hospice and home health care. All fi les include specifi c dates of service and codes for specifi c diagnoses and procedures using either International Classifi cation of Diseases , Ninth Revision , Clinical Modifi cation codes ( 7 ) or Healthcare Common Procedure Coding System ( 8 ) . The currently available SEER -Medicare data include cases diagnosed through the end of 2002.
Sample Selection
From the SEER -Medicare data, we selected all Medicare beneficiaries aged 65 and older who were diagnosed between January 1991 and December 2002 with breast, lung, colorectal, or prostate cancers of stage I, II, III, or IV. Patients were excluded if the month of diagnosis was unknown or if they had been ascertained by the SEER registry through death certificate or autopsy. To capture all services provided, we selected only patients enrolled in Medicare Part A and Part B coverage for 2 months before and 12 months after their cancer diagnosis, thus including Medicare claims through 2003. We also excluded persons enrolled in managed care at any time during this 14-month period because health maintenance organizations (HMOs) do not submit detailed claims data to Medicare. In 1991, the proportion of Medicare beneficiaries enrolled in HMOs was 4%, increasing to 18% in 2002 ( 9 , 10 ) . To avoid capturing costs for treatment deriving from more than one cancer, we required that the patients have no prior or subsequent cancers reported in the SEER data.
Defining Costs and Care
The term costs, as used in this analysis, refers to the amount reimbursed by Medicare. Reimbursement rather than charges has been used as a proxy for medical care costs in other SEER -Medicare cost of care studies ( 5 , 11 ) because Medicare charges are not necessarily related to the cost of providing services ( 12 ) ; by contrast, Medicare costs are actual payments derived from reimbursement formulas that are intended to reflect the average resource utilization for that health service. A previous study concluded that actual payments may be preferred because they most closely correspond to the economic concept of opportunity cost, "a measure of the dollars that become unavailable for purchasing other things in the economy" ( 13 ) .
Although a variety of price adjusters have been used in studies of health-care cost trends ( 14 ) , we used ones that are directly related to Medicare reimbursement formulas. Payments for Medicare Part A (inpatient services) and Part B (outpatient services) were calculated separately. The Hospital Wage Index ( 15 ) and the Medicare Economic Index ( 16 ) were used to adjust for infl ation in Medicare Parts A and B estimates, respectively, during 1991 -2003 ( 14 ) . We also adjusted for geographic variability in costs
CONTEXT AND CAVEATS
Prior knowledge
Little was known about temporal changes in the costs of cancer treatment and which services have contributed to the increases.
Study design
Data from the Surveillance, Epidemiology, and End Results Progam were linked to Medicare claims data to assess the costs of initial cancer care (defined as that occurring from 2 months before diagnosis to 12 months following diagnosis) for persons diagnosed with breast, lung, colorectal, or prostate cancer according to cancer type and type of treatment.
Contribution
The study quantified the increase in the cost of cancer treatment for four major cancers and identified chemotherapies and radiation as contributors to those increases. It thus provided data needed for developing strategies to mitigate costs.
Implications
Costs for hospitalization accounted for the largest portion of expenditures. Expensive chemotherapies will place a strain on the financial resources of the Medicare program.
Limitations
The work does not assess cancer treatment patterns or costs for persons younger than 65, and the assessment was confined to services covered by Medicare To capture all care associated with the initial diagnosis and treatment of cancer, the initial care period was defi ned as care provided from 2 months before diagnosis through 365 days after diagnosis. We used the fi rst day of the month of diagnosis in the SEER fi le as the date of diagnosis unless a cancer surgery was found in the Medicare data in the month before the SEER date. In such cases, the date of surgery from the Medicare data was used as the date of diagnosis.
The assessment included the total of Medicare payments for all health care provided (eg, hospital care, physician services, and outpatient and home health care). In addition, we assessed trends in the costs of major categories of cancer treatment according to cancer site. The categories of treatment were cancer-related surgery, radiation therapy, chemotherapy, and other hospitalizations. Claims for these services were mutually exclusive, meaning that costs were not assigned to more than one category. The categories were defi ned as follows. Cancer-related surgery costs were assessed beginning from the date of surgery, as reported on the Medicare claims, for a defi ned period based on the type of surgery. The length of the cancer-related surgery period was determined according to the intensity of the surgical procedure, and all Medicare claims during this period were included in the estimate of cancer-related surgery costs. In the case of multiple procedures (eg, transurethral resection of the prostate followed by radical prostatectomy), we used a hierarchy of surgical procedures to determine the most invasive surgery, which was considered the cancer-related surgery. The period associated with each surgery and the hierarchy of procedures was developed with the input from a practicing oncologist (E. B. Lamont), and the codes used to defi ne the surgeries are provided in Appendix Table 1 . Radiation therapy included both neoadjuvant therapy and adjuvant treatment. Costs were identifi ed from the physician/supplier (carrier) fi le. In addition, we included claims from radiation therapy reported on the Hospital Outpatient fi le if the only service provided on that claim was radiation therapy. Radiation therapy that appeared on the same outpatient claim along with other services could not be included because the claim only has the total payment; thus, in these cases, costs for radiation therapy could not be separated from payment for other services. The cost of chemotherapy was defi ned as all Medicare payments, excluding radiation therapy claims, from the date on the fi rst chemotherapy claim to the date on the last chemotherapy claim. The rationale for including all Medicare payments except those for radiation is that the vast majority of care that a patient receives while undergoing chemotherapy will be related to either chemotherapy administration or monitoring and treating the effects of the chemotherapy. For persons who had cancer-related surgery, chemotherapy costs included neoadjuvant therapy, if provided, or any adjuvant therapy given after the cancer-related surgery period had ended.
Because of the growing use of erythropoiesis-stimulating agents and granulocyte-colony stimulating factor (G-CSF), we determined the proportion of chemotherapy patients who had a Medicare claim for these medications. We calculated the portion of mean chemotherapy costs that was attributable to physician claims for these agents. Costs for other hospitalizations were defi ned as Medicare payments for any inpatient stays not occurring during the time windows for cancer-related surgery or chemotherapy.
Statistical Analysis
Assessing Trends in Costs. Trends were calculated based on estimates for successive calendar years. For patients whose care spanned more than one calendar year, all costs were assigned to the year of diagnosis. To understand why costs may be changing over time, we assessed them according to two components -the percentage of new patients receiving each type of treatment (ie, surgery, chemotherapy, radiation therapy, and other hospitalizations) and the mean cost of care for patients who received the treatment. For example, the mean cost of cancer-related surgery is based only on those patients undergoing surgery. We assessed whether the trends in costs and in the proportion of people being treated were statistically significant using linear regression models. The models included the year as the independent variable and costs/percentage of people treated as the dependent variable. The slope parameters with 95% confidence intervals (CIs) were calculated for each sitespecific trend.
Estimating National Medicare Costs. Estimates of trends in costs were derived from cost data for Medicare beneficiaries residing in the SEER areas. We extrapolated our estimate of total Medicare fee-for-service payments to the entire United States for each of these cancer sites and services. To do this, we first obtained the total Medicare fee-for-service population aged 65 and older in 2002 from the CMS Web site ( 19 ) . To determine the total number of cancer cases among the Medicare population, we used the 2002 SEER cancer site -specific rate for persons aged 65 and older and applied these rates to the total Medicare population. In the case of breast and prostate cancers, we included only the sex-specific population. To determine the costs of specific service categories, we first estimated the total number of beneficiaries receiving each service. This estimate was derived by calculating, by cancer site, the proportion of patients in our analysis who received the service and multiplying this by the total number of beneficiaries diagnosed with cancer in 2002. Then, to calculate the total Medicare payment for 2002 patients, we multiplied our estimate of the 2002 mean payment for the service by the estimate of total number of Medicare fee-for-service beneficiaries who received the service.
Results
Our cohort consisted of 306 709 fee-for-service Medicare beneficiaries who were diagnosed with breast, lung, colorectal, or prostate cancer between 1991 and 2002 ( Table 1 ) . From 1991 through 2002, there was a statistically signifi cant increase in the initial care costs for lung, breast, and colorectal cancer. In all years, the two largest mean Medicare payments were for lung and colorectal The percentage of people undergoing cancer-related surgery varied by cancer site ( Figure 2, A ) . For breast and colorectal cancer patients, the portion of patients that underwent surgery was in excess of 87% for all years included in the analysis. For persons with lung cancer, the portion treated surgically declined statistically signifi cantly from 61% in 1991 to 52% in 2002 (yearly rate of decline = 0.84%, 95% CI = 0.67% to 1.02%). The greatest change in cancer-related surgery rates occurred in men with prostate cancer, in whom the percentage treated with surgery declined from 54% in 1991 to 24% in 2002 (yearly rate of decline = 2.52%, 95% CI = 2.07% to 2.97%).
We examined trends in the proportion of people who were hospitalized for their surgery among those who had cancer-related surgery. For colorectal cancer, the percent hospitalized was constant over the study period, at approximately 92%. From 1991 to 2002, the percentage of persons who were hospitalized for their surgeries increased from 36% to 44% for lung surgeries and from 81% to 92% for prostate surgeries. The greatest change in hospitalizations was for breast surgeries, for which the number of women hospitalized declined from 82% in 1991 to 47% in 2002. The 2002 mean cost of surgery was highest for colorectal cancer surgery ($24 910) followed by lung ($12 712), prostate ($9080), and breast ($5674) cancer surgery ( Figure 2, B ) . From 1991 to 2002, the mean cost of surgery for lung cancer increased by $2876 (yearly increase in cost $192, 95% CI = $83 to $302). Mean cancer-related surgery costs for breast and prostate cancer declined statistically signifi cantly during the interval (yearly decreases in costs were $169, 95% CI = $138 to $199, and $137, 95% CI = $16 to $257, respectively). Over the period of this study, there was a statistically signifi cant increase in the use of chemotherapy for breast, lung, and colorectal cancers ( Figure 3, A ) . From 1991 to 2002, the proportion of lung cancer patients treated with chemo- Any cancer service  5068  5099  4774 4682  4789  4707  4882  4719  4878  4727  4785  4770  57 880  Cancer-directed surgery  4604  4627  4289 4270  4368  4220  4396  4293  4449  4323  4323  4334  52 496  Chemotherapy  574  638  549  567  599  629  774  867  997  1064  1095  1156  9509  Radiation oncology  1324  1583  1526 1608  1790  1870  2125  2126  2349  2289  2327  2443  23 360  Other hospitalizations  1271  1341  1241 1178  1166  1174  1207  1143  1228  1188  1152  1095  14 384  Lung  Total number of patients  7130  7333  7083 7053  6899  6810  6481  6328  6159  6005  5254  5206  77 741  Cancer-directed surgery  4364  4371  4119 4117  3830  3735  3544  3338  3309  3190  2729  2710  43 356  Chemotherapy  1731  1827  1688 1825  1852  1963  1994  2057  2074  2102  1858  1838  22 809  Radiation oncology  3347  3325  3176 3124  2995  2932  2798  2663  2487  2418  2055  1972  33 therapy rose from 24% to 35% (yearly rate of increase = 1.2%, 95% CI = 1.0% to 1.4%) and the percent of women with breast cancer who received chemotherapy increased from 11% to 24% (yearly rate of increase = 1.3%, 95% CI = 1.0% to 1.6% who received chemotherapy, erythropoiesis-stimulating agents accounted for 8% of the mean costs of chemotherapy; for breast and prostate cancer patients receiving chemotherapy, the portion of mean chemotherapy costs attributable to erythropoiesis-stimulating agents was higher, about 13%. G-CSF accounted for about 4% of the mean costs of chemotherapy for the four cancers. We also calculated the annual percentage of patients receiving radiation therapy between 1991 and 2002. The fraction of breast and prostate cancer patients receiving radiation therapy rose from 26% to 51% and from 33% to 47%, respectively. During this interval, the percent of persons with colorectal cancer who received radiation therapy remained constant and the portion of lung cancer patients receiving radiation therapy declined by 9%. The observed cost of radiation therapy increased by a statistically signifi cant extent for all four cancers. Radiation costs were greatest for prostate cancer, $5629 in 2002. For breast and prostate cancer patients, the mean increase from 1991 to 2002 in the cost of radiation therapy for persons who received it was $2244 and $2657, respectively (breast yearly increase in cost $195, 95% CI = 167 to 222, P < .05; prostate yearly increase in cost $283, 95% CI = 238 to 327, P < .05) ( Figure 4, B ) . There was statistically signifi cant variation by cancer site in the percent of persons who had hospitalizations for reasons other than cancer-related surgery ( Figure 5, A ) . Persons with lung cancer had the highest rates of hospitalizations not related to cancer surgery, about 70% for each year. From 1991 to 2002, the proportion of men with prostate cancer who had hospitalizations in this category declined by 10%. During this interval, the mean payment for those hospitalized for reasons other than surgery increased statistically signifi cantly for breast, lung, and colorectal cancers (yearly increase in mean payment for hospitalizations for reasons other than surgery for breast cancer patients = $169, 95% CI = $16 to $322; yearly increase for lung cancer patients = $126, 95% CI = $22 to $229; yearly increase in cost for colorectal cancer patients = $187, 95% CI = $29 to $344) ( Figure 5, B ) . For colorectal and lung cancers, the diagnoses for these hospitalizations were primarily for cancer or sequela of cancer treatment.
Some patients in our analysis had no initial cancer-related surgery, radiation therapy, or chemotherapy. These were mostly men with prostate cancer; the proportion of prostate cancer patients handled with expectant management rose from 21% in 1991 to 30% in 2002. The portion of lung cancer patients who had no cancerdirected therapy rose from 20% in 1991 to 26% in 2002. By contrast, almost all breast and colorectal cancer patients had some type of cancer treatment.
We estimated total Medicare payments for initial care if the data from the SEER patients were extrapolated to the US Medicare population aged 65 and older ( Table 2 ) . Total Medicare payments in 2002 were the highest for colorectal and lung cancers, at approximately $2.0 billion each. Hospital care, either associated with cancer-related surgery or other hospitalizations, accounted for a large percentage of costs for breast (43%), lung (50%), and colorectal (72%) cancers. Hospital expenditures represented only 33% of all expenditures for prostate cancers. The combination of hospital care, chemotherapy, and radiation therapy accounted for the preponderance of total costs for breast (69%), colorectal (82%), and lung (74%) cancers. However, for prostate cancer, only 50% of the total costs were for hospital care, chemotherapy, and radiation therapy. In 2002, hormone therapy accounted for 7.4% of total Medicare payments for prostate cancer patients.
Discussion
As health-care costs continue to rise, understanding trends in the costs of health care and which components of treatment are contributing to costs will be important in planning for future health costs and setting priorities for allocating resources. To our knowledge, this analysis is the first to assess trends in the costs of specific components of initial cancer care in the United States. We found that for patients with breast, lung, and colorectal cancers, the mean total amount that Medicare paid per patient during the initial period of diagnosis increased by a statistically significant extent from 1991 to 2002. These current trend estimates can be used as baseline data for investigators who wish to model the cost implications of specific emerging technologies and practices using working assumptions about service costs and dissemination ( 20 ) .
Expenses from hospitalizations, those that occurred during the initial cancer surgery period as well as other hospitalizations during the initial year of care, accounted for the largest portion of Medicare payments for these four cancers. We evaluated the reason for other hospitalizations by reviewing the primary diagnosis on all hospital claims after the cancer-related surgery. We found that, for colorectal and lung cancers, the primary diagnosis for a large portion of the subsequent hospitalizations was for cancer or a sequela to the cancer, for example, pleural effusions or anemia. There were fewer cancer-related diagnoses during other hospitalizations for breast and prostate cancers.
During the period of our study, there were statistically significant increases in the proportions of breast, lung, and colorectal cancer patients treated with chemotherapy. These increasing rates may refl ect the response of practitioners to National Institutes of Health Consensus Statements regarding the survival benefi t associated with adjuvant chemotherapy for breast and colorectal cancer ( 21 -24 ) and to the publication of studies throughout the study period regarding the benefi t of chemotherapy for lung cancer ( 25 -27 ) . The increasing percentage of Medicare benefi ciaries who received adjuvant chemotherapy may also be the result of physicians' growing acceptance of the benefi t of chemotherapy in some elderly patients. Historically, the elderly have not been adequately represented in clinical trials, leaving physicians with uncertainty as to the benefi t and risks of adjuvant therapy in their older patients. In recent years, studies using observational data have highlighted underuse of chemotherapy in the elderly cancer patients and have shown that chemotherapy can be tolerated and effective in many elderly patients ( 28 -32 ) .
In addition to an increase in the percent of patients receiving chemotherapy, we found a marked increase in the average payment for those patients who received chemotherapy. We estimated that in 2002, chemotherapy costs during the initial care period ranged from 9% of total payments for colorectal cancers to 20% of total health-care payments for lung cancer. In the mid to late 1990s, new and expensive agents (eg, paclitaxel, docetaxel, and gemcitabine), alone or in combination with existing agents, were shown to provide superior survival benefi ts compared with prior approaches ( 33 ) . The costs of these agents can be substantial. A study found that the lifetime costs of carboplatin with paclitaxel can be up to $12 000 more than those of older regimens like cisplatin plus vinorelbine ( 34 ) . Even with the emergence of newer, more expensive multidrug chemotherapy regimens during this period, we believe that our results underestimate current 2007 chemotherapy costs because our observation period ended before Federal Drug Administration approval of many of the extremely expensive chemotherapeutic agents such as oxaliplatin, cetuximab, erlitonib, and bevacizumab or the dissemination of fi ndings regarding the benefi ts of trastuzumab for some types of breast cancer. Given that many of the new and expensive targeted therapies are used with existing therapies, they may add to rather than substitute for adjuvant therapy costs. Use of these new agents is estimated to dramatically escalate the costs of cancer care. For example, a 2004 report estimated that the addition of cetuximab and bevacizumab for treatment of metastatic colorectal cancer could cost as much as $161 000 in 1 year ( 35 ) . An additional factor that has contributed to the rising costs of chemotherapy is the increased use of erythropoiesis-stimulating agents and G-CSF. However, the costs of erythropoiesis-stimulating agents and G-CSF may be offset by the fact that use of erythropoiesisstimulating agents and G-CSF may allow patients to remain on the recommended schedule of treatment.
We also observed shifts in components of health-care costs that have infl uenced total costs. The mean payment for prostate cancer declined from 1991 through 2002. This decrease can be explained by a 29% drop in cancer-related surgeries. The reduction in the use of radical prostatectomy has been offset by a 14% increase in the use of radiation therapy from 1991 to 2002. In our analysis, the mean costs of cancer-related surgery by year for prostate cancer ranged from $3451 to $7987 higher than the radiation therapy costs. The differences are greater than those in an earlier study ( 36 ) , which found that during the initial period of care radical prostatectomy was $3178 more expensive than radiation therapy. Although we found that the costs associated with cancer-related surgery are greater than for radiation therapy, the mean cost of cancer surgery has been declining while radiation costs have risen.
The portion of women undergoing surgery for breast cancer remained constant over the period of our study. However, the mean cost of cancer-related surgery declined, likely because the growing use of breast conserving surgery has resulted in fewer inpatient hospitalizations. As was the case for prostate cancer, the decline in inpatient procedures for breast cancer has been offset by increases in the number of women receiving radiation therapy. The temporal increases in initial treatment costs observed here (with the exception of prostate cancer) are likely to continue into the near future and, with the recent introduction of new and increasingly expensive chemotherapy and biologic agents, accelerate.
There were limitations to our study beyond the exclusion of more recent chemotherapeutic agents. For patients who were identifi ed as undergoing cancer-directed surgery, the Medicare procedures reported on the claims could have been miscoded. However, earlier studies have found that procedures reported from the Medicare data have high sensitivity and accuracy and that there is strong concordance between the surgeries identifi ed from the Medicare data and those abstracted by the SEER registrars ( 37 -41 ) . Our estimates of costs are incomplete in several ways. Some patients in our study did not receive any cancerdirected therapy that was identifi ed by either the SEER or Medicare data. The percentage of these patients varied by cancer site. It is possible that these patients presented with advanced disease and did not undergo any curative care. We found that, with the exception of prostate cancer patients, 50% -70% of staged patients who did not receive cancer-directed therapy had stage IV disease. Many of the patients who did not have cancerdirected treatment did have hospitalizations throughout the year. These costs would be captured in the "other hospitalization" category. The lack of treatment could also refl ect receipt of care not provided by Medicare (from the Veteran's Administration or paid for by private health insurance through an employer). In addition to services not provided by Medicare, the payments used to estimate costs exclude services not covered by Medicare. Medicare payments do not include any insurance payments secondary to Medicare or the patient's share of expenditures. Estimates for the portion of total health care spending covered by Medicare range from 65% for 1995 to 58% for 1999 ( 42 , 43 ) . Therefore, the estimates provided in our analysis do not refl ect the total cost of care; they refl ect the trends over time in the cost to Medicare. Another limitation is that the cost of radiation therapy was underestimated. Although we could obtain Medicare payments to the radiation oncologist from the physician claims and payments to outpatient facilities, for the years included in our analysis, outpatient claims had a summary payment that included all services billed on the claim. The only outpatient claims that we could attribute to radiation therapy and include in the analysis were those with no other service included in the outpatient bill, about 60% of all outpatient claims with a billed radiation therapy service. Although the cost of radiation therapy was thus underestimated, the rates of radiation therapy use were not affected by the limitation in the claims data, nor did this limitation affect our ability to estimate total Medicare expenditures. Our analysis was also limited by the fact that the national estimates of cancer costs were derived from the SEER areas and were based on the assumption that cancer incidence rates and stages in the SEER areas are representative of the entire country. In addition, these costs were limited to Medicare payment for the initial care period, thus excluding most treatment costs for recurrence or disease progression. Finally, these data do not refl ect the treatment patterns or costs for persons with cancer under age 65.
The US population is aging. As a result, the absolute number of cancer patients who are 65 and older is expected to increase substantially. In addition, the length of cancer survival has increased resulting in increasing numbers of Medicare benefi ciaries with cancer. CMS faces economic challenges as a result of secular changes in the Medicare population and in cancer survivorship.
Beyond the growing number of Medicare benefi ciaries with cancer, the portion of elderly who are being treated is increasing and treatment costs are rising. For the four cancers in our analysis, the total 2002 Medicare expenditures for initial care exceeded $6.7 billion. These data do not refl ect the current (2008) or future costs to the Medicare program related to cancer care. Expensive chemotherapies will place a strain on the fi nancial resources of the Medicare program. CMS needs to anticipate the burden of paying for new chemotherapies and may need to promote programs to identify those patients who may benefi t the most from these expensive treatments. Without planning for the future, paying for care for Medicare benefi ciaries with cancer will be a major component of the spiraling costs of care faced by the Medicare program.
